These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33543660)

  • 21. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Pearce JW; Vansteenkiste DP; Bibi K; Lim S; Robinson Kick G; Castaner LJ; Sinclair J; Chandra S; Nguyen A; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Aug; 197():108130. PubMed ID: 32622066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceroid lipofuscinosis type 2 disease: Effective presymptomatic therapy-Oldest case of a presymptomatic enzyme therapy.
    Breuillard D; Ouss L; Le Normand MT; Denis TS; Barnerias C; Robert MP; Eisermann M; Boddaert N; Caillaud C; Bahi-Buisson N; Desguerre I; Aubart M
    Eur J Neurol; 2024 Sep; 31(9):e16324. PubMed ID: 38693756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report.
    Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C
    Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.
    Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE
    F1000Res; 2021; 10():614. PubMed ID: 35106137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
    Dulz S; Schwering C; Wildner J; Spartalis C; Schuettauf F; Bartsch U; Wibbeler E; Nickel M; Spitzer MS; Atiskova Y; Schulz A
    Br J Ophthalmol; 2023 Oct; 107(10):1478-1483. PubMed ID: 35772852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Robinson Kick G; Ota-Kuroki J; Lim S; Castaner LJ; Jensen CA; Kowal J; Nguyen A; Corado C; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Sep; 198():108135. PubMed ID: 32634395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).
    Gutić M; Milosavljević MN; Safiye T; Milidrag A; Jankovic SM
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):561-570. PubMed ID: 36994735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy.
    Spaull R; Soo AK; Batzios S; Footitt E; Whiteley R; Mink JW; Carr L; Gissen P; Kurian MA
    Neurology; 2024 Aug; 103(3):e209615. PubMed ID: 38976822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
    Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.
    Whiting REH; Jensen CA; Pearce JW; Gillespie LE; Bristow DE; Katz ML
    Exp Eye Res; 2016 May; 146():276-282. PubMed ID: 27039708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal enzyme replacement for inherited retinal diseases.
    Rodriguez-Martinez AC; Wawrzynski J; Henderson RH
    Curr Opin Ophthalmol; 2024 May; 35(3):232-237. PubMed ID: 38170785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
    Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy.
    Wawrzynski J; Martinez AR; Thompson DA; Ram D; Bowman R; Whiteley R; Gan C; Harding L; Mortensen A; Mills P; Gissen P; Henderson RH
    Eye (Lond); 2024 Apr; 38(6):1176-1182. PubMed ID: 38049626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.
    Lu JY; Nelvagal HR; Wang L; Birnbaum SG; Cooper JD; Hofmann SL
    Mol Genet Metab; 2015; 116(1-2):98-105. PubMed ID: 25982063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.
    Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS
    Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies.
    Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S
    Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visual perception and macular integrity in non-classical CLN2 disease.
    Atiskova Y; Wildner J; Wibbeler E; Nickel M; Spitzer MS; Schwering C; Schulz A; Dulz S
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3693-3700. PubMed ID: 35652945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.